+

WO2006125765A3 - Acylated insulin with high purity - Google Patents

Acylated insulin with high purity Download PDF

Info

Publication number
WO2006125765A3
WO2006125765A3 PCT/EP2006/062495 EP2006062495W WO2006125765A3 WO 2006125765 A3 WO2006125765 A3 WO 2006125765A3 EP 2006062495 W EP2006062495 W EP 2006062495W WO 2006125765 A3 WO2006125765 A3 WO 2006125765A3
Authority
WO
WIPO (PCT)
Prior art keywords
insulin
acylated insulin
high purity
weight
acylated
Prior art date
Application number
PCT/EP2006/062495
Other languages
French (fr)
Other versions
WO2006125765A2 (en
Inventor
Jan Markussen
Svend Havelund
Jes Kristian Jacobsen
Aage Hvass
Ib Jonassen
Georg Wilhelm Jensen
Original Assignee
Novo Nordisk As
Jan Markussen
Svend Havelund
Jes Kristian Jacobsen
Aage Hvass
Ib Jonassen
Georg Wilhelm Jensen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, Jan Markussen, Svend Havelund, Jes Kristian Jacobsen, Aage Hvass, Ib Jonassen, Georg Wilhelm Jensen filed Critical Novo Nordisk As
Priority to EP06763218A priority Critical patent/EP1888104A2/en
Publication of WO2006125765A2 publication Critical patent/WO2006125765A2/en
Publication of WO2006125765A3 publication Critical patent/WO2006125765A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is related to a highly purified pharmaceutical preparation comprising an acylated insulin where the acyl group is attached via a linker molecule to the ϵ- amino group of the B29Lys residue of the parent insulin moiety. The insulin pharmaceutical formulation comprises less than about 3% weight/weight of an isomer of the acylated insulin.
PCT/EP2006/062495 2005-05-26 2006-05-22 Acylated insulin with high purity WO2006125765A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06763218A EP1888104A2 (en) 2005-05-26 2006-05-22 Acylated insulin with high purity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200500767 2005-05-26
DKPA200500767 2005-05-26

Publications (2)

Publication Number Publication Date
WO2006125765A2 WO2006125765A2 (en) 2006-11-30
WO2006125765A3 true WO2006125765A3 (en) 2007-02-15

Family

ID=37269816

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/062495 WO2006125765A2 (en) 2005-05-26 2006-05-22 Acylated insulin with high purity

Country Status (2)

Country Link
EP (1) EP1888104A2 (en)
WO (1) WO2006125765A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190010206A1 (en) 2015-08-25 2019-01-10 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
CN108368163A (en) 2015-08-25 2018-08-03 诺和诺德股份有限公司 Novel insulin derivates and its medical usage
CN113226284B (en) * 2018-09-25 2024-12-03 美药星制药股份有限公司 Highly purified recombinant human insulin (RHI) API and its production method
CA3109452A1 (en) 2018-10-01 2020-04-09 Boehringer Ingelheim Vetmedica Gmbh Peristaltic pump and analyzer for testing a sample

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007931A1 (en) * 1993-09-17 1995-03-23 Novo Nordisk A/S Acylated insulin
WO1999021888A1 (en) * 1997-10-24 1999-05-06 Novo Nordisk A/S Aggregates of human insulin derivatives
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007931A1 (en) * 1993-09-17 1995-03-23 Novo Nordisk A/S Acylated insulin
EP1132404A2 (en) * 1993-09-17 2001-09-12 Novo Nordisk A/S Acylated insulin
WO1999021888A1 (en) * 1997-10-24 1999-05-06 Novo Nordisk A/S Aggregates of human insulin derivatives
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes

Also Published As

Publication number Publication date
WO2006125765A2 (en) 2006-11-30
EP1888104A2 (en) 2008-02-20

Similar Documents

Publication Publication Date Title
JP2019523228A (en) Process, pharmaceutical formulation and use thereof for the production of cannabinoid prodrugs
UY29825A1 (en) SUBSTITUTED DERIVATIVES OF 3H-IMIDAZOL- (4.5 B (BETA)) PIRIDINA-2-IL BENZOATES AND BENZAMIDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS
CY1109055T1 (en) 11 - ((4R, 6R) -4,5,6-TRIPHYROXY-3- (R) -Hydroxy-hexylcarbamoyl) -indecaic acid
WO2006125765A3 (en) Acylated insulin with high purity
Aiello et al. Clavaminols A–F, novel cytotoxic 2-amino-3-alkanols from the ascidian Clavelina phlegraea
JP2008546809A (en) Organic compounds
US20160297840A1 (en) Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds
WO2007083060A3 (en) Novel chalcone derivatives with antimitotic activity
WO2007075838A3 (en) Pure and stable tiotropium bromide
WO2005062985A8 (en) Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications
WO2008012442A3 (en) Mixture of partial esters of monopentaerythritol, dipentaerythritol and tripentaerythritol, process for obtaining same and cosmetic product containing them
US20190010137A1 (en) Pseudo-ceramide compound and preparation method therefor
SI1831186T1 (en) A process for the synthesis of valsartan
ES2655655T3 (en) Preparation procedure for alpha-galactosyl ceramide compounds
JP4233262B2 (en) Carbasugar amine derivatives and glycosidase inhibitors using the same
WO2008059513A3 (en) Compounds suitable as modulators of hdl
UA92833C2 (en) Pyrazole analogues
GB0208176D0 (en) Organic compounds
CA2273374C (en) Trioxane dimer compounds having antiproliferative and antitumor activities
USRE38117E1 (en) Trioxane dimer compound having antiproliferative and antitumor activities
GEP20115192B (en) Novel indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them
Earl et al. Synthesis and antileukemic activities of furanyl, pyranyl, and ribosyl derivatives of 4-(3, 3-dimethyl-1-triazeno) imidazole-5-carboxamide and 3-(3, 3-dimethyl-1-triazeno) pyrazole-4-carboxamide
Yong et al. Synthesis of (5R, 8R)-2-(3, 8-Dimethyl-2-oxo-1, 2, 4, 5, 6, 7, 8, 8α-octahydroazulen-5-yl) Acrylic Acid (Rupestonic Acid) Amide Derivatives and in vitro Inhibitive Activities against Influenza A 3, B and Herpes Simplex Type 1 and 2 Virus
WO2007013965A3 (en) Synthesis of scabronines and analogues thereof
US6004997A (en) Trioxane dimer compounds having antiproliferative and antitumor activities

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006763218

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2006763218

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载